Barclays PLC Purchases 12,924 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC increased its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 77,013 shares of the company’s stock after acquiring an additional 12,924 shares during the quarter. Barclays PLC owned about 0.13% of Pyxis Oncology worth $121,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. American Century Companies Inc. boosted its position in shares of Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after buying an additional 140,498 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Pyxis Oncology by 83.0% in the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock worth $458,000 after purchasing an additional 133,018 shares in the last quarter. Sei Investments Co. bought a new position in shares of Pyxis Oncology in the fourth quarter worth $95,000. Aristides Capital LLC bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $193,000. Finally, Commonwealth Equity Services LLC boosted its stake in Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after buying an additional 10,000 shares during the period. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $1.07 on Thursday. The firm has a market capitalization of $66.28 million, a PE ratio of -1.04 and a beta of 1.15. The stock has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.68. Pyxis Oncology, Inc. has a 52-week low of $0.83 and a 52-week high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $16.15 million during the quarter. On average, sell-side analysts forecast that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PYXS shares. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.00.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.